Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
WILMINGTON, Del., March 11, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Horizon Pharma plc (NASDAQ:HZNP)?
- Did you purchase your shares between March 13, 2014 and February 26, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. announces that a complaint has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities that purchased the common stock of Horizon Pharma plc (“Horizon” or the “Company”) (NASDAQ:HZNP) between March 13, 2014 and February 26, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
If you purchased shares of Horizon during the Class Period, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/horizon-pharma-plc-hznp-lawsuit.
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
According to the Complaint, on February 29, 2016, Horizon revealed that in November 2015, the Company had received a subpoena from the U.S. Attorney’s Office for the Southern District of New York requesting documents and information related to its patient assistance programs and other aspects of its marketing and commercialization activities.
On this news, shares of Horizon dropped over 13%, closing at $17.16 per share on February 29, 2016, on heavy trading volume.
If you wish to serve as lead plaintiff, you must move the Court no later than May 9, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
